{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:21:45Z","timestamp":1787664105089,"version":"build-2736575974"},"reference-count":24,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"3","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Endothelial dysfunction, defined by decreased bioavailability of nitric oxide (NO) and increased levels of asymmetric dimethylarginine (ADMA), has been proposed to play a central role in Coronary Artery Disease (CAD) pathophysiology. A selective \u03b2-blocker, nebivolol, could offer benefits in affecting this pathway after revascularization.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    The objective of this study is to determine the influence of nebivolol on serum NO levels and ADMA in patients with CAD who underwent successful elective percutaneous coronary intervention (PCI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    In this prospective randomized double-blind placebo-controlled clinical study, 172 subjects with confirmed obstructive CAD and scheduled for PCI were recruited. After successful revascularization, patients were randomized to receive nebivolol 5 mg once daily (\n                    <jats:italic>n<\/jats:italic>\n                    = 89) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    = 83) for 42 days. Serum NO (\u03bcmol\/L) and ADMA (ng\/mL) were assessed at baseline and day 42 by colorimetry and ELISA, respectively. Paired t-tests and Analysis of Covariance (ANCOVA) analyses were performed for comparisons within and between the groups, respectively, after adjustment for baseline values.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The baseline clinical parameters and biomarker values were found to be equivalent between groups. After 42 days of therapy, there was a marked increase in serum NO levels among the nebivolol group (from 85.25 \u00b1 9.8 to 128.47 \u00b1 6.2;\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001), whereas there was no change in the placebo group (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.85). Simultaneously, there was a decrease in the levels of ADMA in the nebivolol-treated subjects (from 169.68 \u00b112.8 to 153.70 \u00b112.7;\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001) and no change in the placebo-treated group. The ANCOVA analysis between the two groups for both markers was found to be highly significant at Day 42 (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.001), independent of concomitant medications or baseline profiles.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In patients after PCI, treatment for 42 days was found to significantly enhance NO availability and decrease systemic ADMA concentration by nebivolol. These results clearly establish that nebivolol has the potential to restore vascular homeostasis in the high-risk vascular window, hence making it an ideal supplementary treatment for patients having atherosclerotic diseases.\n                  <\/jats:p>","DOI":"10.5339\/qmj.2026.55","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:49:58Z","timestamp":1787662198000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of nebivolol on nitric oxide availability and ADMA concentration in CAD patients after PCI: Prospective randomized double-blind study"],"prefix":"10.5339","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-9202","authenticated-orcid":true,"given":"Ali A.R.","family":"Aldallal","sequence":"first","affiliation":[{"name":"College of Pharmacy, Jabir Ibn Hayyan Medical University, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-1777","authenticated-orcid":true,"given":"Maryam A.","family":"Razzaq","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jabir Ibn Hayyan Medical University, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-4616","authenticated-orcid":true,"given":"Ahmed M. Abdul","family":"Hameed","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jabir Ibn Hayyan Medical University, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3769-379X","authenticated-orcid":true,"given":"Huda Jabber","family":"Merza","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jabir Ibn Hayyan Medical University, Najaf, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-622X","authenticated-orcid":true,"given":"Hasanain Kamil","family":"Hasan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Al-Mustaqbal University, Hillah, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2712-9157","authenticated-orcid":true,"given":"Salam Jasim","family":"Mohammed","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Kufa, Kufa, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3277","reference":[{"issue":"2:","key":"B1","series-title":"Trends Cardiovasc Med","first-page":"140","article-title":"Ischemic heart disease in women: a focus on risk factors","volume":"25","author":"Mehta\n \nPK","year":"2015;","unstructured":"Mehta\n \nPK\n\n, \n\nWei\n \nJ\n\n, \n\nWenger\n \nNK\n\n\n. \nIschemic heart disease in women: a focus on risk factors\n. \nTrends Cardiovasc Med\n. \n2015;\n25\n2:\n140\n51\n. \n\nhttps:\/\/doi.org\/10.1016\/j.tcm.2014.10.005"},{"issue":"1:","key":"B2","series-title":"N Engl J Med","first-page":"54","article-title":"A tale of coronary artery disease and myocardial infarction","volume":"366","author":"Nabel\n \nEG","year":"2012;","unstructured":"Nabel\n \nEG\n\n, \n\nBraunwald\n \nE\n\n\n. \nA tale of coronary artery disease and myocardial infarction\n. \nN Engl J Med\n. \n2012;\n366\n1:\n54\n63\n. \n\nhttps:\/\/doi.org\/10.1056\/NEJMra1112570"},{"issue":"1:","key":"B3","series-title":"Rep Biochem Mol Biol","first-page":"49","article-title":"Oxidative stress status and liver markers in coronary heart disease","volume":"8","author":"Cheraghi\n \nM","year":"2019;","unstructured":"Cheraghi\n \nM\n\n, \n\nAhmadvand\n \nH\n\n, \n\nMaleki\n \nA\n\n, \n\nBabaeenezhad\n \nE\n\n, \n\nShakiba\n \nS\n\n, \n\nHassanzadeh\n \nF\n\n\n. \nOxidative stress status and liver markers in coronary heart disease\n. \nRep Biochem Mol Biol\n. \n2019;\n8\n1:\n49\n56\n. \n\nhttps:\/\/doi.org\/10.29252\/rbmb.8.1.49"},{"issue":"1:","key":"B4","series-title":"N Engl J Med","first-page":"27","article-title":"Regulatory functions of the vascular endothelium","volume":"323","author":"Vane\n \nJR","year":"1990;","unstructured":"Vane\n \nJR\n\n, \n\n\u00c4ngg\u00e5rd\n \nEE\n\n, \n\nBotting\n \nRM\n\n\n. \nRegulatory functions of the vascular endothelium\n. \nN Engl J Med\n. \n1990;\n323\n1:\n27\n36\n. \n\nhttps:\/\/doi.org\/10.1056\/NEJM199007053230106"},{"issue":"Suppl 591","key":"B5","series-title":"Acta Physiol Scand","first-page":"257","article-title":"Studies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor","volume":"139","author":"Furchgott\n \nRF","year":"1990;","unstructured":"Furchgott\n \nRF\n\n\n. \nStudies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor\n. \nActa Physiol Scand\n. \n1990;\n139\nSuppl 591\n257\n70\n. \n\nhttps:\/\/doi.org\/10.1111\/j.1748-1716.1990.tb08936.x"},{"issue":"3:","key":"B6","series-title":"Biochem J","first-page":"593","article-title":"Nitric oxide synthases: structure, function and inhibition","volume":"357","author":"Alderton\n \nWK","year":"2001;","unstructured":"Alderton\n \nWK\n\n, \n\nCooper\n \nCE\n\n, \n\nKnowles\n \nRG\n\n\n. \nNitric oxide synthases: structure, function and inhibition\n. \nBiochem J\n. \n2001;\n357\n3:\n593\n615\n. \n\nhttps:\/\/doi.org\/10.1042\/bj3570593"},{"issue":"16:","key":"B7","series-title":"J Am Coll Cardiol","first-page":"1491","article-title":"Nebivolol: the somewhat-different \u03b2-adrenergic receptor blocker","volume":"54","author":"M\u00fcnzel\n \nT","year":"2009;","unstructured":"M\u00fcnzel\n \nT\n\n, \n\nGori\n \nT\n\n\n. \nNebivolol: the somewhat-different \u03b2-adrenergic receptor blocker\n. \nJ Am Coll Cardiol\n. \n2009;\n54\n16:\n1491\n9\n. \n\nhttps:\/\/doi.org\/10.1016\/j.jacc.2009.05.066"},{"issue":"1:","key":"B8","series-title":"J Cardiovasc Pharmacol Ther","first-page":"44","article-title":"Influence of different \u03b2-blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy","volume":"21","author":"Ignjatovic\n \nV","year":"2016;","unstructured":"Ignjatovic\n \nV\n\n, \n\nPavlovic\n \nS\n\n, \n\nMiloradovic\n \nV\n\n, \n\nAndjelkovic\n \nN\n\n, \n\nDavidovic\n \nG\n\n, \n\nDjurdjevic\n \nP\n\n\n\n. \nInfluence of different \u03b2-blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy\n. \nJ Cardiovasc Pharmacol Ther\n. \n2016;\n21\n1:\n44\n52\n. \n\nhttps:\/\/doi.org\/10.1177\/1074248415587820"},{"issue":"12:","key":"B9","series-title":"Drugs","first-page":"1349","article-title":"A review of nebivolol pharmacology and clinical evidence","volume":"75","author":"Fongemie\n \nJ","year":"2015;","unstructured":"Fongemie\n \nJ\n\n, \n\nFelix-Getzik\n \nE\n\n\n. \nA review of nebivolol pharmacology and clinical evidence\n. \nDrugs\n. \n2015;\n75\n12:\n1349\n71\n. \n\nhttps:\/\/doi.org\/10.1007\/s40265-015-0435-8"},{"issue":"9:","key":"B10","series-title":"Amino Acids","first-page":"1885","article-title":"Plasma homoarginine, arginine, asymmetric dimethylarginine and total homocysteine interrelationships in rheumatoid arthritis, coronary artery disease and peripheral artery occlusion disease","volume":"47","author":"Kayacelebi\n \nAA","year":"2015;","unstructured":"Kayacelebi\n \nAA\n\n, \n\nWillers\n \nJ\n\n, \n\nPham\n \nVV\n\n, \n\nHahn\n \nA\n\n, \n\nSchneider\n \nJY\n\n, \n\nRothmann\n \nS\n\n\n\n. \nPlasma homoarginine, arginine, asymmetric dimethylarginine and total homocysteine interrelationships in rheumatoid arthritis, coronary artery disease and peripheral artery occlusion disease\n. \nAmino Acids\n. \n2015;\n47\n9:\n1885\n91\n. \n\nhttps:\/\/doi.org\/10.1007\/s00726-015-2018-8"},{"issue":"9:","key":"B11","series-title":"Arterioscler Thromb Vasc Biol","first-page":"2039","article-title":"Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes","volume":"20","author":"Fard\n \nA","year":"2000;","unstructured":"Fard\n \nA\n\n, \n\nTuck\n \nCH\n\n, \n\nDonis\n \nJA\n\n, \n\nSciacca\n \nR\n\n, \n\nDi Tullio\n \nMR\n\n, \n\nWu\n \nHD\n\n\n\n. \nAcute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes\n. \nArterioscler Thromb Vasc Biol\n. \n2000;\n20\n9:\n2039\n44\n. \n\nhttps:\/\/doi.org\/10.1161\/01.ATV.20.9.2039"},{"issue":"1 Pt 2","key":"B12","series-title":"Hypertension","first-page":"242","article-title":"Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension","volume":"29","author":"Matsuoka\n \nH","year":"1997;","unstructured":"Matsuoka\n \nH\n\n, \n\nItoh\n \nS\n\n, \n\nKimoto\n \nM\n\n, \n\nKohno\n \nK\n\n, \n\nTamai\n \nO\n\n, \n\nWada\n \nY\n\n\n\n. \nAsymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension\n. \nHypertension\n. \n1997;\n29\n1 Pt 2\n242\n7\n. \n\nhttps:\/\/doi.org\/10.1161\/01.HYP.29.1.242"},{"issue":"5:","key":"B13","series-title":"Scand J Urol Nephrol","first-page":"477","article-title":"The arginine\u2013nitric oxide pathway in thrombotic microangiopathy","volume":"31","author":"Herlitz\n \nH","year":"1997;","unstructured":"Herlitz\n \nH\n\n, \n\nPetersson\n \nA\n\n, \n\nSigstr\u00f6m\n \nL\n\n, \n\nWennmalm\n \n\u00c5\n\n, \n\nWestberg\n \nG\n\n\n. \nThe arginine\u2013nitric oxide pathway in thrombotic microangiopathy\n. \nScand J Urol Nephrol\n. \n1997;\n31\n5:\n477\n9\n. \n\nhttps:\/\/doi.org\/10.3109\/00365599709030647"},{"issue":"2:","key":"B14","series-title":"Atherosclerosis","first-page":"425","article-title":"Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke","volume":"158","author":"Yoo\n \nJH","year":"2001;","unstructured":"Yoo\n \nJH\n\n, \n\nLee\n \nSC\n\n\n. \nElevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke\n. \nAtherosclerosis\n. \n2001;\n158\n2:\n425\n30\n. \n\nhttps:\/\/doi.org\/10.1016\/S0021-9150(01)00451-2"},{"issue":"3:","key":"B15","series-title":"Am J Obstet Gynecol","first-page":"551","article-title":"Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia","volume":"178","author":"Holden\n \nDP","year":"1998;","unstructured":"Holden\n \nDP\n\n, \n\nFickling\n \nSA\n\n, \n\nWhitley\n \nGSJ\n\n, \n\nNussey\n \nSS\n\n\n. \nPlasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia\n. \nAm J Obstet Gynecol\n. \n1998;\n178\n3:\n551\n6\n. \n\nhttps:\/\/doi.org\/10.1016\/S0002-9378(98)70438-6"},{"issue":"1:","key":"B16","series-title":"Kurume Med J","first-page":"1","article-title":"Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis","volume":"47","author":"Miyazaki\n \nH","year":"2000;","unstructured":"Miyazaki\n \nH\n\n\n. \nEndogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis\n. \nKurume Med J\n. \n2000;\n47\n1:\n1\n13\n. \n\nhttps:\/\/doi.org\/10.2739\/kurumemedj.47.1"},{"issue":"7:","key":"B17","series-title":"Arterioscler Thromb Vasc Biol","first-page":"1272","article-title":"Endothelial dysfunction: cardiovascular disease pathophysiology hidden in plain sight","volume":"39","author":"Corban\n \nMT","year":"2019;","unstructured":"Corban\n \nMT\n\n, \n\nLerman\n \nLO\n\n, \n\nLerman\n \nA\n\n\n. \nEndothelial dysfunction: cardiovascular disease pathophysiology hidden in plain sight\n. \nArterioscler Thromb Vasc Biol\n. \n2019;\n39\n7:\n1272\n84\n. \n\nhttps:\/\/doi.org\/10.1161\/ATVBAHA.119.312157"},{"key":"B18","series-title":"Front Med (Lausanne)","first-page":"798958","article-title":"Endothelial dysfunction in hypertension: current concepts and clinical implications","volume":"8:","author":"Gallo\n \nG","year":"2021;","unstructured":"Gallo\n \nG\n\n, \n\nVolpe\n \nM\n\n, \n\nSavoia\n \nC\n\n\n. \nEndothelial dysfunction in hypertension: current concepts and clinical implications\n. \nFront Med (Lausanne)\n. \n2021;\n8:\n798958\n. \n\nhttps:\/\/doi.org\/10.3389\/fmed.2021.798958"},{"issue":"2:","key":"B19","series-title":"Crit Care Clin","first-page":"307","article-title":"Nitric oxide and endothelial dysfunction","volume":"36","author":"Cyr\n \nAR","year":"2020;","unstructured":"Cyr\n \nAR\n\n, \n\nHuckaby\n \nLV\n\n, \n\nShiva\n \nSS\n\n, \n\nZuckerbraun\n \nBS\n\n\n. \nNitric oxide and endothelial dysfunction\n. \nCrit Care Clin\n. \n2020;\n36\n2:\n307\n21\n. \n\nhttps:\/\/doi.org\/10.1016\/j.ccc.2019.12.009"},{"issue":"2:","key":"B20","series-title":"Int J Clin Exp Med","first-page":"4119","article-title":"Association between genetic polymorphisms of ACE, eNOS, DDAH-2 and ADMA, SDMA and NOx with coronary artery disease in Tunisian population","volume":"9","author":"Trim\u00e8che-Othmani\n \nT","year":"2016;","unstructured":"Trim\u00e8che-Othmani\n \nT\n\n, \n\nKammoun\n \nM\n\n, \n\nCallebert\n \nJ\n\n, \n\nAbid\n \nK\n\n, \n\nMaatouk\n \nF\n\n\n. \nAssociation between genetic polymorphisms of ACE, eNOS, DDAH-2 and ADMA, SDMA and NOx with coronary artery disease in Tunisian population\n. \nInt J Clin Exp Med\n. \n2016;\n9\n2:\n4119\n24\n."},{"issue":"2:","key":"B21","series-title":"Curr Top Med Chem","first-page":"180","article-title":"Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?","volume":"13","author":"Bouras\n \nG","year":"2013;","unstructured":"Bouras\n \nG\n\n, \n\nDeftereos\n \nS\n\n, \n\nTousoulis\n \nD\n\n, \n\nGiannopoulos\n \nG\n\n, \n\nChatzis\n \nG\n\n, \n\nTsounis\n \nD\n\n\n\n. \nAsymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?\n. \nCurr Top Med Chem\n. \n2013;\n13\n2:\n180\n200\n. \n\nhttps:\/\/doi.org\/10.2174\/1568026611313020007"},{"key":"B22","series-title":"J Cardiol","first-page":"220","article-title":"Biochemical markers of coronary atherosclerosis: building models and assessing their prognostic value regarding the lesion severity","volume":"34:","author":"Zhatkina\n \nMV","year":"2021;","unstructured":"Zhatkina\n \nMV\n\n, \n\nMetelskaya\n \nVA\n\n, \n\nGavrilova\n \nNE\n\n, \n\nYarovaya\n \nEB\n\n, \n\nMakarova\n \nYK\n\n, \n\nLitinskaya\n \nOA\n\n\n\n. \nBiochemical markers of coronary atherosclerosis: building models and assessing their prognostic value regarding the lesion severity\n. \nJ Cardiol\n. \n2021;\n34:\n220\n22\n. \n\nhttps:\/\/doi.org\/10.18087\/cardio.2021.2.n1266"},{"issue":"6:","key":"B23","series-title":"Vasc Health Risk Manag","first-page":"909","article-title":"A review of the safety and efficacy of nebivolol in the mildly hypertensive patient","volume":"3","author":"John\n \nC","year":"2007;","unstructured":"John\n \nC\n\n\n. \nA review of the safety and efficacy of nebivolol in the mildly hypertensive patient\n. \nVasc Health Risk Manag\n. \n2007;\n3\n6:\n909\n17\n. \n\nhttps:\/\/doi.org\/10.2147\/vhrm.s1815"},{"issue":"4:","key":"B24","series-title":"Arterial Hypertens","first-page":"243","article-title":"Effect of 6-week treatment with nebivolol on blood pressure reduction and echocardiographic indices in patients with essential hypertension","volume":"9","author":"Florczak\n \nE","year":"2005;","unstructured":"Florczak\n \nE\n\n, \n\nMakowiecka-Cie\u015bla\n \nM\n\n, \n\nKlisiewicz\n \nA\n\n, \n\nPuci\u0142owska\n \nB\n\n, \n\nBaranowski\n \nR\n\n, \n\nKorzeniowska-Kubacka\n \nI\n\n\n\n. \nEffect of 6-week treatment with nebivolol on blood pressure reduction and echocardiographic indices in patients with essential hypertension\n. \nArterial Hypertens\n. \n2005;\n9\n4:\n243\n51\n. \n\nhttps:\/\/doi.org\/10.5603\/AH.2005.0038"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2026\/3\/article-55.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2026\/3\/article-55.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2026\/3\/article-55.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:49:58Z","timestamp":1787662198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2026\/3\/article-55.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2026.55","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}